Pilot Study of Tirzepatide Effects on Muscle Mass, Strength, and Vascular Health in Obese Adults Aged 50 and Over

What this Trial Is About

This research aims to study the effects of tirzepatide, a new medication approved for type 2 diabetes and obesity, on muscle mass and function in older adults with obesity. The study focuses on people aged 50 and older, especially since weight loss from tirzepatide might include loss of muscle, which can cause weakness and frailty. The study is a pilot, single-arm, open-label trial conducted in South Texas, where obesity and related diseases are common among aging adults. Participants will self-administer tirzepatide once a week by injection, starting at 2.5 mg with dose increases monthly up to 10 mg or the highest tolerated dose. The treatment period lasts for 6 months. The trial evaluates how tirzepatide affects muscle mass, strength, and vascular health during this time. During the study, participants will undergo assessments of muscle mass, muscle strength, and lower extremity function at the start and after 6 months of treatment. Researchers will monitor changes in these outcomes to understand the impact of tirzepatide on muscle and vascular health. Participants are expected to comply with fasting and other study procedures, and the total duration of involvement is 6 months.

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults